Background: To study the 1-year evolution of quantitative dual-task gait parameters in comparison with single-task gait parameters and detailed neuropsychological assessment in patients with multiple sclerosis (MS) treated with natalizumab. Methods: Walking speed, stride length and stride time during a dual task (walking while forward counting, backward counting, semantic fluency, and phonemic fluency), a single walking task, and a detailed neuropsychological assessment were prospectively measured and assessed twice at the 1-year interval in 9 consecutive patients with MS treated with natalizumab. Results: Dual-task-related gait changes (walking speed, stride length and stride time while performing semantic fluency and walking speed, and stride time while performing phonemic fluency) showed a significant improvement after 1 year of treatment with natalizumab. The single walking task and detailed neuropsychological assessment did not present any modification. Conclusions: Dual-task-related gait changes using a cognitive task with a specific executive demand represent an interesting marker of disease-modifying therapy in patients with MS.

1.
Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F: Gait analysis in demented subjects: interests and perspectives. Neuropsychiatr Dis Treat 2008;4:155-160.
2.
Scheinberg L, Holland N, Larocca N, Laitin P, Bennett A, Hall H: Multiple sclerosis; earning a living. NY State J Med 1980;80:1395-1400.
3.
Amato MP, Zipoli V, Portaccio E: Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006;245:41-46.
4.
Chiaravalloti ND, DeLuca J: Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-1151.
5.
Hamilton F, Rochester L, Paul L, Rafferty D, O'Leary CP, Evans JJ: Walking and talking: an investigation of cognitive-motor dual tasking in multiple sclerosis. Mult Scler 2009;15:1215-1227.
6.
Kalron A, Dvir Z, Achiron A: Walking while talking - difficulties incurred during the initial stages of multiple sclerosis disease process. Gait Posture 2010;32:332-335.
7.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
8.
Van der Linden M, Adam S (eds): L'évaluation des troubles de la mémoire: présentation des quatre tests de mémoire épisodique (avec leur étalonnage). Marseille, Solal, 2004.
9.
Cardebat D, Doyon D, Puel M, Goulet P, Joanette Y: Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990;90:207-217.
10.
Strauss E, Sherman E, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, ed 3. New York, Oxford University Press, 2006, p 8.
11.
Tombaugh TN: Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 2004;19:203-214.
12.
Zimmermann P, Fimm B: Test for attentional performance (TAP). Herzogenrath: PsyTest, 1995.
13.
Godefroy O; GREFEX: Fonctions exécutives et pathologies neurologiques et psychatriques. Marseille, Solal, 2008.
14.
Wechsler D: Wechsler Adult Intelligence Scale, ed 3 (WAIS-3®). San Antonio, Harcourt Assessment, 1997.
15.
Zigmond AS, Snaith RP: The Hospital Anxiety and Depression scale. Acta Psychiatr Scand 1983;67:361-370.
16.
Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C: Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing 2005;34:614-619.
17.
Mattioli F, Stampatori C, Capra R: The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011;32:83-88.
18.
Mattioli F, Stampatori C, Bellomi F, Capra R: Natalizumab efficacy on cognitive impairment in MS. Neurol Sci 2011;31(suppl 3):321-323.
19.
Belachew S, Phan-Ba R, Bartholome E, Delvaux V, Hansen I, Calay P, et al: Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2010;18:240-245.
20.
Sheridan PL, Solomont J, Kowall N, Hausdorff JM: Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer's disease. J Am Geriatr Soc 2003;51:1633-1637.
21.
Allali G, Dubois B, Assal F, Lallart E, de Souza LC, Bertoux M, et al: Frontotemporal dementia: pathology of gait? Mov Disord 2010;25:731-737.
22.
Pashler H: Dual-task interference in simple tasks: data and theory. Psychol Bull 1994;116:220-244.
23.
Allali G, Kressig RW, Assal F, Herrmann FR, Dubost V, Beauchet O: Changes in gait while backward counting in demented older adults with frontal lobe dysfunction. Gait Posture 2007;26:572-576.
24.
Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O: Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc 2008;56:946-947.
25.
Armand S, Allet L, Landis T, Beauchet O, Assal F, Allali G: Interest of dual-task-related gait changes in idiopathic normal pressure hydrocephalus. Eur J Neurol 2011;18:1081-1084.
26.
Duncan RP, Earhart GM: Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil Neural Repair 2012;26:132-143.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.